Fully automated insulin delivery: artificial pancreas

Abstract

Despite the increasing use of new treatment options, the glycaemic control of most diabetes patients is not satisfactory. However, a clear advantage is documented in the subpopulation of patients applying advanced technologies. Nevertheless, there is a need to improve the replacement of islet function and to check the achievement of treatment goals in individuals with diabetes. Aiming to fulfil these requirements, new technologies need to attain. Parallel development of insulin pumps and continuous glucose monitoring devices lead to automated insulin delivery systems. The future development goal is to achieve systems not dependent on user inputs, e.g. the fully closed loop system (artificial pancreas). The biggest barriers are the non-physiological insulin delivery and glucose monitoring subcutaneous/interstitial) of the systems used currently, therefore further research will establish the long-term benefits of emerging technologies in the care of diabetes individuals.